Cardiologs Technologies SAS

Cardiologs Technologies SAS specializes in innovative, cloud-based arrhythmia diagnostic solutions powered by artificial intelligence, enhancing cardiac care through advanced software tools that integrate seamlessly into clinical workflows. Founded in 2014 in Paris, France, Cardiologs Technologies SAS focuses on providing advanced arrhythmia diagnostics. The company was acquired by Koninklijke Philips N. V.

in November 2021 from investors including Bpifrance Investissement Régions and Alven. Jia Li, the founder, led the company through its evolution and strategic pivots, securing a total of EUR 10. 005 mn in funding, with the latest round being Series A, which was led by Alven and completed on 2021-11-08. The company has engaged in 5 investment deals to date, with a current valuation of EUR 41.

323 mn. Cardiologs specializes in advanced arrhythmia diagnostic solutions that are cloud-based, vendor-neutral, and enhanced by artificial intelligence. Their core products include a unique software solution designed for remote cardiac monitoring, capable of detecting over 20 types of arrhythmia events through clinically validated algorithms. This technology primarily serves clinicians, hospitals, and cardiac service providers aiming to enhance their diagnostic capabilities.

The products are marketed globally, with a strong presence in key markets such as North America, Europe, and various regions in Asia. In the most recent year, 2022, Cardiologs Technologies SAS reported a revenue of EUR 4,769,014. 30 and an EBITDA of EUR -9,718,911. 10.

The company generates revenue through a subscription-based model, allowing healthcare providers to access its arrhythmia diagnostic software and form partnerships with hospitals for tailored solutions. Following the acquisition by Koninklijke Philips N. V. , Cardiologs is positioned to expand its cardiac diagnostics and monitoring portfolio.

The company aims to introduce new product offerings designed to enhance cardiac diagnostic capabilities further. Additionally, there are plans to penetrate new markets, focusing on regions in North America and Asia by 2024. The recent funding will facilitate these initiatives, supporting product development and strategic market expansion efforts.